SecBot SecBot
S-3 ·Filed Nov 13, 2026

DCOY

Decoy Therapeutics Inc.
BEARISH
Impact 6/10
Horizonweeks Processed3d 7h ago SEC0001193125-26-460860
Shelf registration (potential dilution)
Actionable Insight ▼ Bearish

Monitor for prospectus supplements that would trigger actual sales under the shelf. The company's cash runway into early 2027 makes near-term drawdowns likely. Any offering would be highly dilutive relative to the $3M market cap.

DirectionBearish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Decoy Therapeutics filed a universal shelf registration statement on Form S-3 to register up to $50 million in securities (common stock, preferred stock, warrants, debt securities, units). The filing comes one day after the company's 10-Q disclosed a going concern warning, cash runway only into early 2027, and a market cap of $3M. The shelf is a capital-raising tool for a pre-revenue biotech with urgent funding needs.

Key Financial Metrics

Offering Size
$50.0M

Key Facts

  • Shelf registration of up to $50,000,000 in securities (common, preferred, warrants, debt, units).
  • Market cap is approximately $3M; public float is approximately $2.5M (68,748 shares held by non-affiliates).
  • Company has a going concern warning; cash expected to fund operations only into early 2027.
  • 18 offering/registration filings in the last 24 months, indicating repeated capital raises.
  • Nasdaq listing at risk due to potential MVLS Rule ($5M minimum market value) and existing Mandatory Panel Monitor through March 2027.
  • No revenue from product sales; pre-clinical stage biotechnology company.

Financial Impact

Up to $50 million in potential dilution, which is approximately 17x current market cap of $3M. Any actual issuance would be massively dilutive.

dilutioncash runwaymarket cap

Risk Factors

  • Massive dilution risk: $50M shelf is 17x current market cap.
  • Going concern risk: cash only into early 2027; company needs capital urgently.
  • Nasdaq delisting risk: market cap below proposed $5M MVLS threshold; company under Mandatory Panel Monitor.
  • Repeated capital raises (18 filings in 24 months) suggest structural funding dependency.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-460860
Document: dcoy-ex5_1.htm0001193125-26-460860
Document: dcoy-exfiling_fees.htm0001193125-26-460860
Document: dcoy-ex23_1.htm0001193125-26-460860
Document: 0001193125-26-460860-index-headers.html0001193125-26-460860
Document: 0001193125-26-460860-index.html0001193125-26-460860
Document: 0001193125-26-460860.txt0001193125-26-460860

Track record

13 reports on DCOY

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +67.67% at T+60 after the Jun 29, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Bearish 6/10 Viewing Entry $1.02 Now $0.9010 +11.66% settles Dec 15
  2. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $1.11 Now $0.9010 −18.83% settles Dec 2
  3. Oct 19, 202629d ago EFFECT Neutral 4/10 Entry $1.17 to $0.9752 Now $0.9010 −22.99% ▼ −16.65% −13.19% vs SPY
  4. Oct 7, 20265w ago S-1 Bearish 6/10 Entry $1.52 to $1.14 Now $0.9010 +40.72% ▲ +25.00% +19.71% vs SPY
  5. Sep 23, 20267w ago 8-K Bearish 6/10 Entry $3.11 to $1.03 Now $0.9010 +71.03% ▲ +66.88% +66.46% vs SPY
  6. Aug 4, 202614w ago DEFA14A Neutral 3/10 Entry $4.19 to $2.98 Now $0.9010 −78.50% ▼ −28.88% −28.28% vs SPY
  7. Jul 20, 202617w ago EFFECT Neutral 4/10 Entry $5.31 to $3.52 Now $0.9010 −83.02% ▼ −33.65% −37.77% vs SPY
  8. Jun 29, 202620w ago 8-K Bearish 7/10 Entry $9.59 to $5.04 Now $0.9010 +90.60% ▲ +47.45% +47.17% vs SPY
  9. Jun 25, 202620w ago EFFECT Neutral 5/10 Entry $5.92 to $4.94 Now $0.9010 −84.78% ▼ −16.53% −17.05% vs SPY
  10. Jun 4, 202623w ago DEFA14A Neutral 3/10 Entry $6.71 to $7.31 Now $0.9010 −86.57% ▲ +8.94% +10.31% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 9h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026